Right, dual ABL/Src inhibitors such as dasatinib and ponatinib inhibit blinatumomab-induced T-cell activation in vitro. Left, the in vivo effects on T cells may be less pronounced because of intermittent inhibition of Src kinases and additional effects of regulatory T cells. BiTE, bispecific T-cell engager.